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sion and logistic regression models were used to evaluate the effect of pharmacist 
intervention on patients’ A1c levels after controlling for gender, baseline age, baseline
A1c values, ethnicity, smoking status, insurance, and the duration between the index 
date and last visit. RESULTS: A total of 484 patients were included in the analysis: 
222 who received pharmacist intervention, and 262 receiving usual care. The change
in A1c between baseline and last visit was 1.7 percentage points in the intervention 
group, 1.1 percentage points with usual care. The estimated impact of the pharma-
cists’ interventions was 1.38 percentage points (p  0.0001) after adjusting for dif-
ferences in patient characteristics using ordinary least squares regression techniques.
Similarly, the pharmacist intervention increased the likelihood of achieving the treat-
ment goal of an A1c 7% by four-fold (OR  4.037, p  0.0001). CONCLUSIONS:
Pharmacist interventions do have signiﬁ cant beneﬁ t for patients with diabetes. The 
results demonstrate the importance of the pharmacist in diabetes control and can be
applied to similar clinics serving mostly uninsured Hispanic patients.
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OBJECTIVES: To investigate the effectiveness of a pay-for-performance program
(P4P) to increase quality care processes and decrease hospitalization among diabetics. 
METHODS: The study sample consisted of diabetic members 18 to 75 years of age 
enrolled in a Preferred Provider Organization (PPO) from 1999 to 2006, as identiﬁ ed 
by the administrative claims data. We used multivariate analyses to assess the impact
of seeing P4P-participating providers on the receipt of quality of care (i.e., at least two
hemoglobin A1c (HbA1c) and one low-density-lipoprotein (LDL) tests) and hospital-
izations while controlling the following characteristics: age, gender, comorbidity, 
number of outpatient visits, number of distinct primary care physicians seen, seen by 
a endocrinologist, insulin dependence, and calendar year. RESULTS: Diabetics who 
saw P4P-participating providers were signiﬁ cantly more likely to receive quality care
when compared to diabetics who did not (OR 1.16, 95%CI 1.11–1.22, p  0.001).
Diabetics who received quality care were signiﬁ cantly less likely to be hospitalized in
the following year when compared to diabetics who did not (IRR 0.80, 95% CI 
0.80–0.85, p  0.001). Although in a one-year period, there was no difference in hos-
pitalization rates between diabetics who saw P4P-participating providers and those
who did not, diabetics who saw P4P-participating providers in 2004 through 2006
(i.e., three-consecutive years) were signiﬁ cantly less likely to be hospitalized in 2006 
when compared to those who did not (IRR 0.75, 95% CI 0.61–0.93, p  0.01). 
CONCLUSIONS: We found that among diabetics in a PPO setting, a P4P can signiﬁ -
cantly increase quality care processes and decrease hospitalization rates. Further 
research should focus on deﬁ ning the impact of P4P on intermediary outcomes such
as HbA1c and LDL levels.
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OBJECTIVES: Normoglycaemia in people with diabetes results in improved outcome. 
Continuous glucose monitoring provides detailed diagnostic information used to opti-
mise therapy. The objective of this study was to review randomised controlled trials 
(RCTs) of the only device available for blinded, professional use. METHODS: Pub-
lished studies using the MiniMed Continuous Glucose Monitoring System (CGMS,
Medtronic Inc., Northridge, CA) were identiﬁ ed using appropriate search terms in a 
series of clinical databases including: Medline, Pubmed, Google Scholar and Scientiﬁ c 
Web of Knowledge. Other measures were also taken such as searching the reference 
lists and review by recognised experts. RESULTS: Seven randomised controlled trials
were identiﬁ ed, ﬁ ve in children. Double-blinding was not possible. Although HbA1c 
was explicitly stated as the primary endpoint in four studies the studies were only
adequately powered to detect large, between-group minimum differences (range 0.5 
to 1.0% HbA1c). Only two studies included subjects with type-2 diabetes. Other 
endpoints included the frequency of hypoglycaemia and hyperglycaemia events.
Within-group HbA1c decreases were observed in all but one study. The crude, 
weighted mean improvement in HbA1c across the studies using the device was 0.6% 
(range 0% to 0.8%). No studies recorded how the information was utilised to modify 
treatment, such as changes in dose titration or treatment regimen. CONCLUSIONS:
Devices such as the professional CGMS provide detailed diagnostic information.
However, any consequent changes in care and outcome can only result from the 
appropriate application of this information. Although there was a notable improve-
ment in glucose control (HbA1c), existing studies were largely underpowered and did 
not capture the resulting treatment changes that could lead to improved outcome.
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OBJECTIVES: Examine the impact of patient self-reported diabetes knowledge on 
diabetes self management and outcomes and assess whether diabetes knowledge
inﬂ uences patient preferences for a once weekly (QW) injectable therapy versus daily 
oral medications. METHODS: A nationally representative random sample of patients 
with self-reported type-2 diabetes (n  1516) participated in an on-line survey. Regres-
sion analyses were used to explore the relationship between self-reported diabetes
knowledge, health outcomes, and preferences for QW therapy. RESULTS: Mean age
of the sample was 57.5 years, 52% were men, and mean duration of diabetes was
9.7 years. Self-rated knowledge of diabetes ranged from “extremely knowledgeable”
(9% of patients) to “very knowledgeable” (31%), “knowledgeable” (38%), “some-
what knowledgeable” (21%) and “not knowledgeable” (1%). Adjusted for demo-
graphic factors (age, gender, diabetes duration, education level), higher level of 
knowledge was associated with self-reported improvement in health since diagnosis,
both physical (beta  0.15) and emotional (beta  0.18), and better self-care adherence,
including dietary (beta  0.14), exercise (beta  0.11), medication (beta  0.12) and 
blood glucose monitoring recommendations (beta  0.18) (p  0.001 for all included
variables). When asked to consider potential advantages of a QW injectable medica-
tion if superior blood glucose control and similar safety could be achieved as compared 
to a daily oral medication, preference for a QW approach was positively associated 
with diabetes knowledge (OR 1.18, p  0.03), after adjustment for demographics and 
past and present experience with self-injected medications (43%). Assuming same
blood glucose control and safety, overall, 54% of patients stated a preference for once
weekly versus daily injectable diabetes medication. CONCLUSIONS: Higher levels 
of self-reported diabetes knowledge are associated with greater improvement in 
self-reported health, as well as adherence to diabetes self-care behaviors. Patients who
report higher levels of diabetes knowledge may be more willing to consider new treat-
ment options, such as a once weekly injectable therapy for diabetes.
INFECTION – Clinical Outcomes Studies
PIN1
STATISTICAL ANALYSIS OF MONONUCLEOSIS IN ADOLESCENTS
LaRue CL
University of Louisville, Louisville, KY, USA
OBJECTIVES: Mononucleosis is a non-fatal disease that is most widely seen in the 
adolescent ages of teenagers and toddlers. Mono is caused by the Epstein-Barr virus; 
a member of the herpes virus family and one of the most common human viruses, 
affecting as many as 95% of adults between 35 and 40 years of age. When infection 
with EBV occurs during adolescence or young adulthood, it causes mononucleosis 
35% to 50% of the time. Our objective is to use data from the National Inpatient
Sample for 2005, conducted by the Agency for Healthcare Research and Quality to 
explain these and other correlations with respect to mononucleosis. METHODS:
Within the sample, there were 2000 observations of patients with mono and 1814 
without mono. The SAS statistical analysis software was used to produce table, graphi-
cal, and regression analysis to explain data correlations and discrepancies among the
diseased population and the non-diseased population or the control group. RESULTS:
Demographic variables of gender and race were normally distributed within the 
disease group. Procedures of injection of antibiotic, venous catheterization, biopsy of 
bone marrow, tonsillectomy with adenoidectmy, along with diagnosis of disorder of 
ﬂ uid, acute tonsillitis, acute pharyngitis, general symptoms, peritonsillar abscess, and 
other symptoms involving abdomen and pelvis were seen as predictive variables cor-
related with having the disease. Because a wide array of procedures were seen in the 
disease population, the most common procedure classiﬁ cations were extracted and 
used to perform regression analysis. CONCLUSIONS: Procedure classes of other
operations on lung and bronchus, incision, excision, and anastonmosis of intestine, 
along with incision, excision, and occlusion of vessels, and operations on bone marrow
and spleen were found to be the best indicators of predicting length of stay and total 
charges of the diseased group.
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OBJECTIVES: Pneumonia is a bacterial or viral infection that affects the lungs, and
makes it difﬁ cult to breath. This disease can cause hospitalization and sometimes
death. It is the purpose of this study to examine a group of pediatric patients with 
pneumonia and factors such as sex, length of stay, Charlson Index, age and hospital 
expenses to determine how they are related to the disease. METHODS: Data were 
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taken from the 2005 National Inpatient Sample. One-way frequencies, summary sta-
tistics, table analysis, logistic regression, linear regression, and kernel density were all 
used to evaluate the data. We used exploratory data analysis to investigate patient 
outcomes. There were 5622 patients with pneumonia and a control group of 5600
patients. RESULTS: Pneumonia affects 1–2 year olds more than older children. Most 
of the patients had a Charlson number of 0, indicating non-severe conditions. Out of 
5622 patients, there were 73 fatalities. The majority of patients had a hospital expense
of $2,000 to $12,000. Sex did not play a huge factor in the distribution of patient
deaths. The mean age was 7.29 years old. The mean length of stay was 9.41 days. 
Patient procedure and diagnosis codes were analyzed to discover which codes had the
most signiﬁ cant impact on patients, length of stay, and total hospital charges. Patients
with additional diseases were analyzed to see if there was a signiﬁ cant difference in
hospital length of stay and total hospital charges. CONCLUSIONS: Patients have 
different hospital costs, lengths of stay, initial diagnosis, procedures and outcomes
according to their sickness, and how they can be treated. Most patients that come into
the hospital do not have to stay too long, have a moderate hospital expense, and are
generally young children. Pneumonia is a serious illness, occasionally fatal, but it can
usually be treated successfully.
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OBJECTIVES: The primary objective is to compare candidemia treatment success
between micafungin and caspofungin. Secondary objectives are to identify cost and
mortality rates associated with the use of micafungin versus caspofungin. METHODS:
This was a retrospective chart review of patients who received one dose of micafungin 
or caspofungin during their hospitalization in a regional VA medical center between
January 1, 2004 and February 29, 2008. A combination of electronic data extraction
and manual chart review was performed on each subject’s medical record for patient
characteristics, risk factors, antifungal use prior and post echinocandin, adverse drug
reactions associated with echinocandins, microbiological eradication, clinical success,
length of stay, total hospital cost, and echinocandin cost. All statistical tests were
two-tailed with p-value of less than 0.05 considered statistically signiﬁ cant. RESULTS:
A total of 106 patients with at least one positive bloodstream or sputum culture for 
C. albicans or C. non-albicans were included. Treatment groups had similar baseline
characteristics in all areas except more micafungin patients had renal failure (p 
0.016), prior antifungal use (p  0.021) and post antifungal use (p  0.002). Treatment 
success rates were comparable among groups (74% micafungin compared to 64% 
caspofungin, p  0.279). Microbiological success was 54% vs. 45% (p  0.367) for 
micafungin vs. caspofungin, respectively. There was no difference in microbiological
success between C. albicans and C. non-albicans for micafungin (p  0.802), however, 
a signiﬁ cant difference was seen in the caspofungin patients (C. albicans 35% vs. 59% 
C. non-albicans, p  0.05). Total cost of patient care (p  0.027) and echinocandin 
overall cost (p  0.001) were signiﬁ cantly lower in the micafungin group. Length of 
stay and mortality rates were comparable among groups. CONCLUSIONS: We found
overall treatment success was non-inferior among micafungin and caspofungin 
therapies.
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OBJECTIVES: Achieving sustained virologic response (SVR) could prevent further
transmission of hepatitis C virus (HCV) and reduce chronic hepatitis C (CHC) inci-
dence; we developed a compartment model to describe the dynamics of HCV transmis-
sion in the United States. METHODS: This population model was expressed by partial
differential equations across compartments based on: injection-drug use, CHC infec-
tion, diagnosis, genotypes, treatment/re-treatment, SVR and disease progression.
Model inputs were based on published sources. Model was calibrated from 2002–
2006 and matched closely with CDC reports and other published literature. The cali-
brated model was then applied to assess the CHC burdens from 2007–2040 under 
the current pegylated-interferon/ribavirin (P/R) treatment strategy. A scenario from a
hypothetical new CHC regimen (NEW) was also assessed. This included: NEW avail-
able in 2011 (70% SVR) for genotype-1, treatment-naïve patients; P/R treatment-
failure patients (TFs) re-treated by NEW with 50% SVR; NEW not used to treat
genotype-2/3 patients; P/R durations consistent with current treatment guidelines by
genotypes and costs $28,000/48-week; diagnosis and treatment rates remain unchanged
with NEW. All costs were converted into 2007 dollars using 3% discount rate. 
RESULTS: Under P/R, US CHC prevalence at 2040 is projected to be around 1.7 
million. Overall CHC direct medical cost is about $6 billion a year under P/R, only
13% of which is treatment-related; the remaining 87% comes from managing the
comorbidities and long-term consequences of advanced liver disease (ALD) among 
undiagnosed patients, diagnosed-but-never-treated patients, and TFs. Compared to
P/R, NEW is projected to cure 351,448 more patients, prevent 23,444 more CHC
incidences, avert 103,953 more ALD incidence, and prevent 39,929 more deaths from 
2007–2040. CHC prevalence at 2040 under NEW is projected to be 335,000 fewer 
patients. CONCLUSIONS: A new CHC regimen may have a higher public health 
impact than P/R. Costs unrelated to current CHC treatment with P/R are the major 
burden of hepatitis C.
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OBJECTIVES: The objective of the study was to explore the applicability of pharma-
cogenomics in ART (Antiretro viral therapy). METHODS: Pharmacogenomic studies
in HIV patients were identiﬁ ed from the database of WHO, Pubmed, Clinical trials.
gov and relevant grey literature from 2000–2008. Two reviewers independently 
extracted data. RESULTS: Pharmacogenomics provides a powerful support to inves-
tigate variable responses to antiretroviral therapy. To date, few antiretrovirals appear 
to have a clear genotype–phenotype correlation. However, such correlations have
been demonstrated for CYP2B6 and efavirenz disposition, HLA-B*5701 and abacavir 
hypersensitivity, and UGT1A1 and atazanavir hyperbilirubinemia. Clinically signiﬁ -
cant and conﬁ rmed pharmacogenomic relationships were identiﬁ ed for three ART 
drugs. Out of 405 studies, 6/202 studies were identiﬁ ed as relevant to CYP2B6 and
efavirenz disposition (2RCTs, 1 nRCT and 3 pharmacokinetic studies). Three (3/118) 
studies were identiﬁ ed for HLA-B*5701 and abacavir hypersensitivity (2 RCTs and 1
nRCT) and 2/85 studies for UGT1A1 and atazanavir hyperbilirubinemia (1RCT and 
1nRCT). Studies (2/6) revealed that genotype and sex were identiﬁ ed as predictive 
covariates of efavirenz disposition. Studies (2/3) across the world have consistently 
demonstrated that HLA-B*5701 predicts the likelihood of hypersensitivity reactions
to abacavir. As a consequence, pharmacogenetic screening for HLA-B*5701 has
entered routine clinical practice and is recommended in most guidelines before starting 
an abacavir containing regimen. Studies (1/2) show that polymorphisms at MDR1-
3435 signiﬁ cantly inﬂ uence atazanavir plasma concentrations, although ATV plasma 
concentrations directly correlate with bilirubin levels, the risk of severe hyperbilirubi-
nemia is further increased in the presence of the UGT1A1-TA7 allele. CONCLU-
SIONS: Although the wider applicability of pharmacogenomic relationships is 
prevalent and its use in clinical practice is still limited. Pharmacogenomics can greatly 
contribute in taking more adequate therapeutic decisions and to optimise treatment 
for HIV/AIDS.
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PAPILLOMAVIRUS
Peercy DP
University of Louisville, Louisville, KY, USA
OBJECTIVES: The human papillomavirus is the most common sexually transmitted 
disease in America. This virus will affect 6.2 million Americans this year. Most cases 
of HPV come from sexual contact or vaginal delivery from an infected mother. It is the 
objective of this study to gain more knowledge about HPV in order to be able to control
or prevent the spreading of this virus. METHODS: A data set of over 22,000 pediatric
patients from the 2005 National Inpatient Sample was used for analysis with SAS 
Enterprise Guide to examine different characteristics of HPV. From SAS, we were able 
to set up one way frequencies, pie charts, kernel densities, and logistic and linear
regressions to compare and contrast different aspects of HPV. We also examined patient 
diagnosis and procedure codes. RESULTS: The most prominent age groups affected 
by HPV are young children and adolescents. This is a concern since there is a strong 
relationship to cervical cancer in later life. Although two types of the virus (16 and 18)
are responsible for 70% of cervical cancers, less than 1% of the patients in our sample 
died with HPV. This virus is not costly to detect or treat with the majority of the patients 
charged around $5,000 from hospitalization with the virus. We found that 90% of 
patients with a URI also had HPV. We found many statistically signiﬁ cant relationships 
between demographics, procedures, and diagnoses, and length of stay or total charges 
of the patient. CONCLUSIONS: Further research is still needed for doctors to be able 
to prevent or cure HPV. Trial medications are out on the market targeting young
females, but surprisingly, more males have HPV because they are the carriers of this 
virus. We need to focus more time and money to ﬁ nd a cure for HPV.
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OBJECTIVES: Cellulitis is a skin infection caused by bacteria. In children, cellulitis 
most often occurs on the face, legs, arms, or around the area near the anus. It can 
usually be treated with antibiotics (oral or topical). However, if not treated, the infec-
tion can spread and cause far more serious conditions such as meningitis or blood clots
in the legs. The objective of this paper is to explore the data of pediatric patients who 
have cellulitis and to compare the results to patients who do not have the disease. Basic
variables such as age, race, and gender are examined along with recorded patient 
diagnosis and procedure codes. METHODS: The statistical software SAS was used to
analyze and explore the data supplied by the National Inpatient Sample for 2005. The
dataset contained 1287 patients with cellulitis and a control group of 1300 without 
cellulitis. Statistical methods used include one-way frequencies, kernel densities,
summary statistics, table analyses, logistic regression, and linear regression. We also 
examined the most frequent patient diagnoses and procedures for the patients in the 
dataset. RESULTS: The patients represented by the data are all pediatric. About 63% 
of patients with cellulitis are male, with about 37% female. The age group with the 
highest concentration of patients is 0–3 with about 29% of the total. Only 0.08% of 
the patients with cellulitis actually died. In general, the disease is not fatal. The average 
